Dorothea Lesche

Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity

Dorothea Lesche, Sam Mostafa, Ian Everall, Christos Pantelis, Chad A Bousman

Journal article  |  2020  |  PHARMACOGENOMICS JOURNAL

Clozapine is an atypical antipsychotic metabolized by CYP1A2, CYP2D6, and CYP2C19 enzymes. Among 66 adult schizophrenia patients t..

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ

Michael S Toss, Asima Abidi, Dorothea Lesche, Chitra Joseph, Sakshi Mahale, Hugo Saunders, Tanjina Kader, Islam M Miligy, Andrew R Green, Kylie L Gorringe, Emad A Rakha

Journal article  |  2020  |  BRITISH JOURNAL OF CANCER

BACKGROUND: The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast ductal carcinoma in situ (DCIS) is ..

Evaluation of genomic changes in ductal carcinoma in situ as potential biomarkers of recurrence risk

Dorothea Lesche, Hugo Saunders, Sakshi Mahale, Magnus Zenthoven, Siobhan Huges, Tanjina Kader, Niko Thio, Islam M Miligy, Jia-Min Pang, Andrew R Green, Emad A Rakha, Ian G Campbell, Stephen B Fox, Kylie Gorringe

Conference Proceedings  |  2020  |  CANCER RESEARCH

Kluver-Bucy Syndrome Following Traumatic Brain Injury: A Systematic Synthesis and Review of Pharmacological Treatment From Cases in Adolescents and Adults

Fiona J Clay, Anu Kuriakose, Dorothea Lesche, Amelia J Hicks, Hadar Zaman, Elham Azizi, Jennie L Ponsford, Mahesh Jayaram, Malcolm Hopwood

Journal article  |  2019  |  JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Klüver-Bucy syndrome (KBS) is a rare clinical presentation following traumatic brain injury (TBI). Symptoms include visual agnosia..

Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography

Christian Zanchin, Kyohei Yamaji, Carolin Rogge, Dorothea Lesche, Thomas Zanchin, Yasushi Ueki, Stephan Windecker, Paul Mohacsi, Lorenz Raber, Vilborg Sigurdardottir

Journal article  |  2018  |  PLOS ONE

BACKGROUND: The purpose of the present study was to assess the short- and long-term progression of cardiac allograft vasculopathy ..

Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement

Dorothea Lesche, Vilborg Sigurdardottir, Alexander B Leichtle, Christos T Nakas, Uwe Christians, Lars Englberger, Martin Fiedler, Carlo R Largiader, Paul Mohacsi, Johanna Sistonen

Journal article  |  2018  |  METABOLOMICS

INTRODUCTION: The immunosuppressive therapy with everolimus (ERL) after heart transplantation is characterized by a narrow therape..

Does centrifugation matter? Centrifugal force and spinning time alter the plasma metabolome

Dorothea Lesche, Roland Geyer, Daniel Lienhard, Christos T Nakas, Gaelle Diserens, Peter Vermathen, Alexander B Leichtle

Journal article  |  2016  |  METABOLOMICS

BACKGROUND: Centrifugation is an indispensable procedure for plasma sample preparation, but applied conditions can vary between la..

Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation

Dorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, Lars Englberger, Georg M Fiedler, Carlo R Largiader, Paul Mohacsi, Johanna Sistonen

Journal article  |  2015  |  CLINICAL TRANSPLANTATION

BACKGROUND: Everolimus (ERL) has become an alternative to calcineurin inhibitors (CNIs) due to its renal-sparing properties, espec..

CYP3A5*3 and POR*28 Genetic Variants Influence the Required Dose of Tacrolimus in Heart Transplant Recipients

Dorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, Markus Oberhaensli, Thierry Carrel, Georg M Fiedler, Carlo R Largiader, Paul Mohacsi, Johanna Sistonen

Journal article  |  2014  |  THERAPEUTIC DRUG MONITORING

BACKGROUND: After heart transplantation (HTx), the interindividual pharmacokinetic variability of immunosuppressive drugs represen..